Department of Hematology;
Peking Union Medical College Hospital;
Beijing 100730;
China;
Department of Hematology;
Shanxi Provincial Cancer Hospital;
Taiyuan 030013;
China;
Department of Hematology;
Fourth Hospital of Hebei Medical University;
Shijiazhuang 050011;
China;
Department of Hematology;
Chinese PLA General Hospital;
Beijing 100039;
China;
Department of Lymphoma;
the 307 Hospital of PLA;
Beijing 100071;
China;
Department of Lymphoma;
Peking University Cancer Hospital and Institute;
Beijing 100142;
China;
Department of Lymphoma;
Tianjin Medical University Cancer Institute and Hospital;
National Clinical Research Center for Cancer;
Key Laboratory of Cancer Prevention and Therapy;
Tianjin;
Tianjin’s Clinical Research Center for Cancer;
Tianjin 300060;
China;
Department of Hematology;
Beijing Friendship Hospital;
Beijing 100050;
China;
Department of Hematology;
Peking University Third Hospital;
Beijing 100191;
China;
Department of Hematology;
the First Affiliated Hospital of Harbin Medical University;
Harbin 150081;
China;
Department of Hematology;
Peking University First Hospital;
Beijing 100034;
China;
Department of Hematology;
Beijing Hospital;
Beijing 100730;
China;
Department of Lymphoma;
Harbin Medical University Cancer Hospital;
Harbin 150081;
China;
Lymphoma Diagnosis and Treatment Center;
Institute of Hematology and Blood Diseases Hospital;
Tianjin 300052;
China;
Department of Hematology;
Second Hospital of Hebei Medical University;
Shijiazhuang 050000;
China;
Department of Hematology;
Shanxi Provincial People’s Hospital;
Taiyuan 030012;
China;
Department of Hematology;
Beijing Tongren Hospital;
Beijing 100730;
China;
Columbia University Medical Center;
New York 10032-3784;
NY;
USA;
Peripheral T-cell lymphoma; chidamide; histone deacetylase inhibitor; epigenetic;